EA200401506A1 - Рекомбинантный поксвирус, экспрессирующий гомологичные гены, встроенные в поксвирусный геном - Google Patents

Рекомбинантный поксвирус, экспрессирующий гомологичные гены, встроенные в поксвирусный геном

Info

Publication number
EA200401506A1
EA200401506A1 EA200401506A EA200401506A EA200401506A1 EA 200401506 A1 EA200401506 A1 EA 200401506A1 EA 200401506 A EA200401506 A EA 200401506A EA 200401506 A EA200401506 A EA 200401506A EA 200401506 A1 EA200401506 A1 EA 200401506A1
Authority
EA
Eurasian Patent Office
Prior art keywords
poxvirus
expressing
homological
genes
integrated
Prior art date
Application number
EA200401506A
Other languages
English (en)
Other versions
EA012160B1 (ru
Inventor
Пол Хаули
Соня Лейрер
Original Assignee
Бавариан Нордик А/С
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Бавариан Нордик А/С filed Critical Бавариан Нордик А/С
Publication of EA200401506A1 publication Critical patent/EA200401506A1/ru
Publication of EA012160B1 publication Critical patent/EA012160B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/863—Poxviral vectors, e.g. entomopoxvirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Данное изобретение относится к рекомбинантному поксвирусному вектору, способному экспрессировать две или более гомологичных чужеродных последовательности, которые получены из разных вариантов микроорганизма и которые имеют гомологию 50% или выше. Изобретение, кроме того, относится к способу получения такого рекомбинантного поксвируса и применению указанного рекомбинантного поксвируса в качестве лекарственного средства или вакцины. Кроме того, предлагается способ воздействия, предпочтительно индуцирования иммунного ответа в существующем животном, включая человека.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200401506A 2002-05-16 2003-05-14 Рекомбинантный поксвирус, экспрессирующий гомологичные гены, встроенные в поксвирусный геном, и его применение EA012160B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200200753 2002-05-16
DKPA200200752 2002-05-16
PCT/EP2003/005047 WO2003097846A1 (en) 2002-05-16 2003-05-14 Recombinant poxvirus expressing homologous genes inserted into the poxviral genome

Publications (2)

Publication Number Publication Date
EA200401506A1 true EA200401506A1 (ru) 2005-04-28
EA012160B1 EA012160B1 (ru) 2009-08-28

Family

ID=29551228

Family Applications (3)

Application Number Title Priority Date Filing Date
EA200401507A EA007811B1 (ru) 2002-05-16 2003-05-14 Межгенные области, используемые в качестве инсерционных сайтов в геноме модифицированного вируса коровьей оспы анкара (mva)
EA200401506A EA012160B1 (ru) 2002-05-16 2003-05-14 Рекомбинантный поксвирус, экспрессирующий гомологичные гены, встроенные в поксвирусный геном, и его применение
EA200900180A EA020230B1 (ru) 2002-05-16 2003-05-14 Рекомбинантный модифицированный вирус осповакцины анкара (mva), экспрессирующий гомологичные последовательности, встроенные в поксвирусный геном, и его применение

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EA200401507A EA007811B1 (ru) 2002-05-16 2003-05-14 Межгенные области, используемые в качестве инсерционных сайтов в геноме модифицированного вируса коровьей оспы анкара (mva)

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA200900180A EA020230B1 (ru) 2002-05-16 2003-05-14 Рекомбинантный модифицированный вирус осповакцины анкара (mva), экспрессирующий гомологичные последовательности, встроенные в поксвирусный геном, и его применение

Country Status (23)

Country Link
US (14) US7550147B2 (ru)
EP (3) EP2253709B1 (ru)
JP (4) JP4693092B2 (ru)
KR (4) KR101138067B1 (ru)
CN (6) CN1653183B (ru)
AT (1) ATE315660T1 (ru)
AU (4) AU2003242540A1 (ru)
BR (2) BRPI0311178B8 (ru)
CA (3) CA2481521C (ru)
DE (1) DE60303218T2 (ru)
DK (2) DK1407033T3 (ru)
EA (3) EA007811B1 (ru)
ES (1) ES2256776T3 (ru)
HK (2) HK1076642A1 (ru)
IL (4) IL164177A0 (ru)
MX (2) MXPA04011194A (ru)
NO (3) NO334273B1 (ru)
NZ (2) NZ536501A (ru)
PL (2) PL218318B1 (ru)
PT (1) PT1407033E (ru)
SI (1) SI1407033T1 (ru)
UA (1) UA82479C2 (ru)
WO (2) WO2003097846A1 (ru)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4101327C1 (ru) * 1991-01-18 1991-10-24 Mercedes-Benz Aktiengesellschaft, 7000 Stuttgart, De
NZ524661A (en) * 2000-11-23 2005-03-24 Bavarian Nordic As Modified vaccinia ankara virus variant
EP1839672A3 (en) * 2002-04-19 2007-11-21 Bavarian Nordic A/S Modified vaccinia virus Ankara for the vaccination of neonates
EA007811B1 (ru) 2002-05-16 2007-02-27 Бавариан Нордик А/С Межгенные области, используемые в качестве инсерционных сайтов в геноме модифицированного вируса коровьей оспы анкара (mva)
US7501127B2 (en) 2002-05-16 2009-03-10 Bavarian Nordic A/S Intergenic regions as novel sites for insertion of HIV DNA sequences in the genome of Modified Vaccinia virus Ankara
KR101044538B1 (ko) * 2002-09-05 2011-06-27 버베리안 노딕 에이/에스 무혈청 조건하에서 일차세포의 배양 및 바이러스의 증식방법
JP5052893B2 (ja) * 2003-02-20 2012-10-17 アメリカ合衆国 ポックスベクターにおける新規の挿入部位
GB2402391A (en) * 2003-06-04 2004-12-08 Oxxon Pharmaccines Ltd Fowlpox recombinant genome
US7951576B2 (en) * 2004-11-05 2011-05-31 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods for preparing cells and viruses
BRPI0608310A2 (pt) 2005-02-23 2009-12-08 Bavarian Nordic As uso de um poxvìrus modificado para a indução rápida de imunidade contra um poxvìrus ou outros agentes infecciosos
EP2027271A4 (en) * 2006-05-19 2010-06-09 Glycofi Inc RECOMBINANT VECTORS
WO2008142479A2 (en) * 2006-08-25 2008-11-27 The Government Of The United States Of Amercia, As Represented By The Secretary, Department Of Health And Human Services Intergenic sites between conserved genes in the genome of modified vaccinia ankara (mva) vaccinia virus
EP2426142A3 (en) 2006-10-16 2012-06-13 Genelux Corporation Modified vaccinia virus strains for use in a diagnostic and therapeutic method
EP2086526B1 (en) * 2006-11-09 2014-07-23 The United States Of America As Represented By The Secretary of the Navy Induction of an immune response against Dengue virus using prime-boost approach
US8440202B2 (en) * 2006-11-09 2013-05-14 The United States Of America As Represented By The Secretary Of The Navy Induction of an immune response against dengue virus using the prime-boost approach
EP2390340A3 (en) * 2007-01-30 2012-02-22 Transgene SA vector encoding Papillomavirus E1 and E2 polypeptides with reduced percentage of identity
US8268327B2 (en) 2007-04-27 2012-09-18 Bavarian Nordic A/S Immediate protection against pathogens via MVA
MX2009012272A (es) * 2007-05-15 2009-12-01 Transgene Sa Vectores para la expresion de genes multiples.
WO2008150404A1 (en) * 2007-05-30 2008-12-11 Wyeth Raccoon poxvirus expressing genes of feline antigens
TW200907058A (en) * 2007-05-30 2009-02-16 Wyeth Corp Raccoon poxvirus expressing rabies glycoproteins
EP2207564B1 (en) 2007-10-18 2016-10-05 Bavarian Nordic A/S Use of mva to treat prostate cancer
US20110052627A1 (en) * 2008-06-20 2011-03-03 Paul Chaplin Recombinant modified vaccinia virus measles vaccine
KR100894430B1 (ko) * 2008-11-11 2009-04-22 시스템디엔디(주) 초음파, 음향 및 온도변화를 이용한 밸브의 유체누설 측정장치 및 이를 이용한 유체누설 측정방법
JP2012509073A (ja) * 2008-11-21 2012-04-19 バヴァリアン・ノルディック・アクティーゼルスカブ 複数の相同ヌクレオチド配列を含むベクター
EA201270108A1 (ru) 2009-10-08 2012-08-30 Бавариан Нордик А/С Формирование полиспецифического t-клеточного ответа против вич у человека
EP2488649B1 (en) 2009-10-16 2019-04-03 The U.S.A. as represented by the Secretary, Department of Health and Human Services Recombinant modified vaccinia ankara (mva) vaccinia virus containing restructured insertion sites
US20110159031A1 (en) * 2009-12-22 2011-06-30 Baxter International Inc. Vaccine to Influenza A Virus
EP2552490A4 (en) * 2010-03-26 2013-12-18 Emergent Product Dev Gaithersburg Inc INFLUENZA MATRIX 2 PROTEIN ECKTOMOMAS, EXPRESSION SYSTEM THEREFOR AND USES THEREOF
US10087423B2 (en) 2010-07-20 2018-10-02 Bavarian Nordic A/S Method for harvesting expression products
CN103200962A (zh) * 2010-09-23 2013-07-10 巴克斯特国际公司 重组病毒载体及用于诱导对黄热病毒的免疫反应的方法
US9173933B2 (en) 2010-10-15 2015-11-03 Bavarian Nordic A/S Recombinant modified vaccinia virus Ankara influenza vaccine
JP6415977B2 (ja) 2011-04-15 2018-10-31 ジェネラックス・コーポレイションＧｅｎｅｌｕｘ Ｃｏｒｐｏｒａｔｉｏｎ 弱毒化ワクシニアウイルスのクローン株およびその使用方法
EP2788021B1 (en) 2011-12-09 2017-01-18 Bavarian Nordic A/S Poxvirus vector for the expression of bacterial antigens linked to tetanus toxin fragment c
EP2620446A1 (en) 2012-01-27 2013-07-31 Laboratorios Del Dr. Esteve, S.A. Immunogens for HIV vaccination
AU2013271338B2 (en) 2012-06-05 2018-05-24 The Australian National University Vaccination with interleukin-4 antagonists
EA201891945A3 (ru) 2012-08-01 2019-05-31 Бавариан Нордик А/С Вакцина рекомбинантного модифицированного вируса осповакцины анкара (mva) респираторно-синцитиального вируса (rsv)
WO2014043535A1 (en) 2012-09-14 2014-03-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compositions for the treatment of cancer
US20140140959A1 (en) 2012-10-05 2014-05-22 Aladar A. Szalay Energy Absorbing-Based Diagnostic and Therapeutic Methods Employing Nucleic Acid Molecules Encoding Chromophore-Producing Enzymes
US20150283220A1 (en) 2012-10-19 2015-10-08 Bavarian Nordic, Inc. Methods and compositions for the treatment of cancer
MY193724A (en) * 2013-03-15 2022-10-27 Sementis Ltd Immune modulation
WO2014139587A1 (en) * 2013-03-15 2014-09-18 Okairòs Ag Improved poxviral vaccines
DE102013004595A1 (de) 2013-03-15 2014-09-18 Emergent Product Development Germany Gmbh RSV-Impfstoffe
US10238700B2 (en) 2014-01-02 2019-03-26 Genelux Corporation Oncolytic virus adjunct therapy with agents that increase virus infectivity
KR101645642B1 (ko) 2014-10-16 2016-08-11 대한민국 Kvac１０３ 유래의 재조합 백시니아 바이러스
KR101623498B1 (ko) 2014-10-16 2016-05-24 대한민국 약독화 백시니아 바이러스주 kvac１０３
CA2977660A1 (en) 2015-02-25 2016-09-15 Memorial Sloan-Kettering Cancer Center Use of inactivated nonreplicating modified vaccinia virus ankara (mva) as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors
CA2982896A1 (en) 2015-04-17 2016-10-20 Memorial Sloan Kettering Cancer Center Use of modified vaccinia ankara virus (mva) or mva with a deletion of virulence factor e8 as immunotherapeutic agent against solid tumors
KR20160140075A (ko) * 2015-05-29 2016-12-07 코오롱생명과학 주식회사 폭스바이러스 유래 프로모터 및 이를 포함하는 벡터
CN107709554A (zh) * 2015-06-15 2018-02-16 巴法里安诺迪克有限公司 重组经修饰痘苗病毒安卡拉(mva)口蹄疫病毒(fmdv)疫苗
FR3042121A1 (fr) 2015-10-08 2017-04-14 Jean-Marc Limacher Composition anti-tumorale
CN106591361A (zh) * 2015-10-20 2017-04-26 钱文斌 一种重组痘溶瘤病毒及其构建方法和应用
EP3402802B1 (en) 2016-01-08 2023-04-12 Geovax, Inc. Compositions and methods for generating an immune response to a tumor associated antigen
PL3407910T3 (pl) 2016-01-29 2022-08-16 Bavarian Nordic A/S Rekombinowana zmodyfikowana szczepionka przeciwko wirusowi krowianki ankara (mva) przeciwko wirusowi zapalenia mózgu koni
BR112018015696A2 (pt) * 2016-02-03 2018-12-26 Geovax Inc composições e métodos para gerar uma resposta imune para um flavivírus
MX2018010231A (es) 2016-02-25 2019-06-06 Memorial Sloan Kettering Cancer Center Mva recombinante o mvadele3l que expresa el flt3l humano y uso de los mismos como agentes inmunoterapéuticos contra tumores sólidos.
MX2018010204A (es) 2016-02-25 2019-05-06 Memorial Sloan Kettering Cancer Center Virus de la vaccinia atenuada competentes para replicacion con la supresion de timidina quinasa con y sin la expresion del flt3l o gm-csf humanos para inmunoterapia del cancer.
EP3452087A1 (en) 2016-05-02 2019-03-13 Janssen Vaccines & Prevention B.V. Therapeutic hpv vaccine combinations
MX2019001919A (es) * 2016-08-19 2019-09-04 Sementis Ltd Vacunas virales.
EP3518656A4 (en) * 2016-09-30 2020-09-30 Monsanto Technology LLC METHOD OF SELECTING TARGETS FOR SITE-SPECIFIC GENOME MODIFICATION IN PLANTS
CN111107872A (zh) 2017-05-12 2020-05-05 纪念斯隆-凯特林癌症中心 有用于癌症免疫疗法的牛痘病毒突变体
MA49397A (fr) * 2017-06-15 2020-04-22 Bavarian Nordic As Vecteurs à poxvirus codant pour des antigènes du vih, et leurs procédés d'utilisation
US11311612B2 (en) 2017-09-19 2022-04-26 Geovax, Inc. Compositions and methods for generating an immune response to treat or prevent malaria
WO2019216929A1 (en) * 2018-05-11 2019-11-14 City Of Hope Mva vectors for expressing multiple cytomegalovirus (cmv) antigens and use thereof
CN111979204B (zh) * 2019-05-24 2023-10-13 杭州功楚生物科技有限公司 携带海绵凝集素基因的溶瘤痘苗病毒、构建方法及用途
CA3161633A1 (en) 2019-11-14 2021-05-20 Aelix Therapeutics, S.L. Dosage regimens for vaccines
TW202203966A (zh) * 2020-03-31 2022-02-01 澳大利亞商賽門蒂斯公司 用於防範ｃｏｖｉｄ－１９之以減毒的痘病毒載體為底質之疫苗
WO2024011250A1 (en) 2022-07-08 2024-01-11 Viromissile, Inc. Oncolytic vaccinia viruses and recombinant viruses and methods of use thereof

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5338683A (en) * 1981-12-24 1994-08-16 Health Research Incorporated Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins
JPH0795956B2 (ja) * 1986-09-22 1995-10-18 京都大学長 ポックスウイルス由来発現制御領域
US5093258A (en) * 1988-08-26 1992-03-03 Therion Biologics Corporation Recombinant fowlpox virus and recombination vector
US5225336A (en) * 1989-03-08 1993-07-06 Health Research Incorporated Recombinant poxvirus host range selection system
US5651972A (en) 1989-04-21 1997-07-29 University Of Florida Research Foundation, Inc. Use of recombinant swine poxvirus as a live vaccine vector
MY109299A (en) * 1990-08-15 1996-12-31 Virogenetics Corp Recombinant pox virus encoding flaviviral structural proteins
US5514375A (en) 1990-08-15 1996-05-07 Virogenetics Corporation Flavivirus recombinant poxvirus vaccine
US6893845B1 (en) * 1990-09-28 2005-05-17 Applied Molecular Evolution, Inc. Surface expression libraries of heteromeric receptors
EP0575491B1 (en) * 1991-03-07 2003-08-13 Virogenetics Corporation Genetically engineered vaccine strain
BE1004877A3 (fr) * 1991-05-27 1993-02-16 Solvay Virus de l'avipox recombinant, culture de cellules infectees par ce virus et vaccins pour la volaille derives de ce virus.
FR2679249B1 (fr) * 1991-07-15 1993-11-26 Centre Nal Recherc Scientifique Souches de levure avec integration stable de genes heterologues.
EP0597016A4 (en) 1991-07-26 1996-04-24 Virogenetics Corp Infectious bursal disease virus recombinant poxvirus vaccine.
EP0538496B1 (en) * 1991-08-26 2003-10-29 Baxter Healthcare S.A. Recombinant fowlpox virus with intact FPV-tk-gene
EP0561034B1 (en) * 1991-08-26 1999-06-09 IMMUNO Aktiengesellschaft Direct molecular cloning of a modified chordopox virus genome
US5676950A (en) 1994-10-28 1997-10-14 University Of Florida Enterically administered recombinant poxvirus vaccines
UA68327C2 (en) * 1995-07-04 2004-08-16 Gsf Forschungszentrum Fur Unwe A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals
EP0753581A1 (en) * 1995-07-10 1997-01-15 Immuno Ag Improved recombinant eukaryotic cytoplasmic viruses, method for their production and their use as vaccines
DE19629828A1 (de) * 1996-07-24 1998-01-29 Bayer Ag Carbanilide
AU4556597A (en) * 1996-09-24 1998-04-17 Bavarian Nordic Research Institute A/S Recombinant mva virus expressing dengue virus antigens, and the use thereof in vaccines
AUPP380598A0 (en) * 1998-05-29 1998-06-25 Commonwealth Scientific And Industrial Research Organisation Genetically manipulated entomopoxvirus
US6252871B1 (en) 1998-07-01 2001-06-26 Powerwave Technologies, Inc. Switchable combiner/splitter
US20040265324A1 (en) * 1999-03-23 2004-12-30 Cardosa Mary Jane Recombinant MVA virus expressing dengue virus antigens, and the use thereof in vaccines
US6682742B1 (en) * 1999-05-28 2004-01-27 Gsf Forschungszentrum Fur Unwelt Und Gesundheit Gmbh Vector for integration of heterologous sequences into poxviral genomes
WO2001068820A1 (en) * 2000-03-14 2001-09-20 Anton Mayr Altered strain of the modified vaccinia virus ankara (mva)
CA2341356C (en) 2000-04-14 2011-10-11 Transgene S.A. Poxvirus with targeted infection specificity
US7034141B2 (en) 2000-08-29 2006-04-25 Wyeth Holdings Corporation Packaging of positive-strand RNA virus replicon particles
NZ524661A (en) 2000-11-23 2005-03-24 Bavarian Nordic As Modified vaccinia ankara virus variant
EA007811B1 (ru) 2002-05-16 2007-02-27 Бавариан Нордик А/С Межгенные области, используемые в качестве инсерционных сайтов в геноме модифицированного вируса коровьей оспы анкара (mva)
US7501127B2 (en) 2002-05-16 2009-03-10 Bavarian Nordic A/S Intergenic regions as novel sites for insertion of HIV DNA sequences in the genome of Modified Vaccinia virus Ankara
PT1567653E (pt) * 2002-11-25 2007-10-01 Bavarian Nordic As Poxvírus recombinante que compreende pelo menos dois promotores do vírus da varíola bovina ati

Also Published As

Publication number Publication date
EP2253709B1 (en) 2018-04-11
EA020230B1 (ru) 2014-09-30
HK1076642A1 (en) 2006-01-20
KR101138067B1 (ko) 2012-04-24
BR0310051A (pt) 2005-02-15
ATE315660T1 (de) 2006-02-15
CA2481799C (en) 2014-01-28
JP2005525823A (ja) 2005-09-02
AU2003242540A1 (en) 2003-12-02
JP4895505B2 (ja) 2012-03-14
PL372088A1 (en) 2005-07-11
PL372093A1 (en) 2005-07-11
CN102199628A (zh) 2011-09-28
KR101005630B1 (ko) 2011-01-05
PT1407033E (pt) 2006-05-31
KR20040108798A (ko) 2004-12-24
US7550147B2 (en) 2009-06-23
US20110053260A1 (en) 2011-03-03
EA007811B1 (ru) 2007-02-27
AU2008255213A1 (en) 2009-01-08
HK1076836A1 (en) 2006-01-27
EP2253709A1 (en) 2010-11-24
CN100494388C (zh) 2009-06-03
US20090311746A1 (en) 2009-12-17
CN1653183A (zh) 2005-08-10
EA200401507A1 (ru) 2005-06-30
ES2256776T3 (es) 2006-07-16
EA012160B1 (ru) 2009-08-28
IL193087A (en) 2012-10-31
EP1506301A1 (en) 2005-02-16
CN1653183B (zh) 2012-07-25
IL193087A0 (en) 2009-02-11
US20120178157A1 (en) 2012-07-12
KR101041691B1 (ko) 2011-06-14
AU2009200380A1 (en) 2009-02-19
US20120039936A1 (en) 2012-02-16
DK1506301T3 (da) 2014-07-21
CA2481521A1 (en) 2003-11-27
US9109233B2 (en) 2015-08-18
CN1653184A (zh) 2005-08-10
US20110244574A1 (en) 2011-10-06
NO334273B1 (no) 2014-01-27
IL164177A0 (en) 2005-12-18
IL193088A (en) 2015-02-26
KR20040108809A (ko) 2004-12-24
UA82479C2 (ru) 2008-04-25
MXPA04010713A (es) 2005-03-07
AU2009200380B2 (en) 2009-10-01
NO20044940L (no) 2004-11-12
CA2481521C (en) 2012-04-17
NO20111324A1 (no) 2011-09-29
JP5777199B2 (ja) 2015-09-09
US8741308B2 (en) 2014-06-03
NO336489B1 (no) 2015-09-07
NZ536502A (en) 2005-10-28
US8288125B2 (en) 2012-10-16
US20130243813A1 (en) 2013-09-19
US20100173388A1 (en) 2010-07-08
US20120135501A1 (en) 2012-05-31
US8309326B2 (en) 2012-11-13
US20100303856A1 (en) 2010-12-02
US20060165727A1 (en) 2006-07-27
EP1407033A1 (en) 2004-04-14
JP2010259446A (ja) 2010-11-18
JP2011004755A (ja) 2011-01-13
BRPI0311178B1 (pt) 2020-11-17
JP4693092B2 (ja) 2011-06-01
AU2003236646B2 (en) 2009-01-15
US20050244428A1 (en) 2005-11-03
WO2003097845A1 (en) 2003-11-27
CA2812019A1 (en) 2003-11-27
US7964374B2 (en) 2011-06-21
EA200900180A1 (ru) 2009-08-28
KR20120002627A (ko) 2012-01-06
MXPA04011194A (es) 2005-02-14
PL216760B1 (pl) 2014-05-30
AU2003236646A1 (en) 2003-12-02
DK1407033T3 (da) 2006-05-22
US7338662B2 (en) 2008-03-04
US20110053259A1 (en) 2011-03-03
JP2005525822A (ja) 2005-09-02
PL218318B1 (pl) 2014-11-28
CN102703393A (zh) 2012-10-03
US20110250693A1 (en) 2011-10-13
US8414900B2 (en) 2013-04-09
US8034354B2 (en) 2011-10-11
DE60303218T2 (de) 2006-09-14
DE60303218D1 (de) 2006-04-06
US8435543B2 (en) 2013-05-07
EP1506301B1 (en) 2014-04-30
AU2009200380C1 (en) 2010-03-11
SI1407033T1 (sl) 2006-06-30
IL193088A0 (en) 2009-02-11
CN101831411A (zh) 2010-09-15
BR0311178A (pt) 2005-03-29
IL164172A0 (en) 2005-12-18
NO20045480L (no) 2004-12-16
WO2003097846A1 (en) 2003-11-27
US20120082696A1 (en) 2012-04-05
EP1407033B1 (en) 2006-01-11
CA2481799A1 (en) 2003-11-27
CN102719408A (zh) 2012-10-10
BRPI0311178B8 (pt) 2021-05-25
NZ536501A (en) 2006-08-31
AU2008255213B2 (en) 2011-10-06
KR20100110901A (ko) 2010-10-13

Similar Documents

Publication Publication Date Title
EA200401506A1 (ru) Рекомбинантный поксвирус, экспрессирующий гомологичные гены, встроенные в поксвирусный геном
WO2003104270A3 (en) GENES OF DUDULINE 2, EXPRESSION PRODUCTS, NON-HUMAN ANIMAL MODEL: USES IN HUMAN HEMATOLOGICAL DISEASES
IL146937A (en) Method for producing a progeny library comprised of polynucleotide sequences
ATE181572T1 (de) Ospa proteine von borrelia burgdorferi untergruppen, dafür kodierende gene sowie impfstoffe
GB0109297D0 (en) Vaccine
ATE228016T1 (de) Lebendvakzine zur behandlung von tumorerkrankungen
DE60229962D1 (de) Verringerung der virulenz von mycobacterium tuberculosis und tuberkuloseschutz mittels inaktivierung des phop-gens
DE69533102D1 (de) Analog von haemophilus hin47 mit verminderter protease aktivität
DE69833876D1 (de) Zusammensetzungen und methoden zur zielgerichteten abgabe von biologisch aktivenfaktoren
DE60117053D1 (de) Herstellung rekombinanter künstlicher hefe-chromosome, welche das genom des humanen cytomegalovirus enthalten
ATE310747T1 (de) Impfstoff gegen geflügelkokzidose
PT815233E (pt) NOVAS CITOCINAS AVIÁRIAS E SEQUjNCIAS GENÉTICAS QUE AS CODIFICAM
HK1080712A1 (en) Ihnv g protein for immune stimulation
UA104993C2 (ru) Рекомбинантный поксовирус, экспрессирующий гомологичные гены, вставленные в поксвирусный геном
NO20052525L (no) Spleisevariant av humant hypofyseveksthormon
FR2809960B1 (fr) Composition adjuvante de la reponse immunitaire comprenant la proteine fha ou un fragment de la proteine fha sous forme libre, et composition immunogene ou vaccinale contenant une telle composition adjuvante
AR046937A1 (es) Proteina nmb0928 y su uso en formulaciones farmaceuticas
AP2003002944A0 (en) Method to generate non virulent microorganisms from pathogenic ones through permanent genetic modification of their biological membrane for vaccine production.
WO2005054281A3 (es) Proteína nmb1125 y su uso en formulaciones farmaceuticas

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KZ KG MD TJ TM